glp-1 agonist cardiovascular outcomes receptor agonists and cardiorenal in type 2 diabetes: an updated meta-analysis of eight CVOTs | Diabetology GLP-1RAs reduce cardiovascular deaths in

Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes

14,28,29,30,31,32,33,34 As most of the trials compared GLP-1RA to placebo, only indirect comparisons between GLP-1RA and other glucose-lowering agents commonly used in clinical practice could be drawn from network meta-analyses

From initial consultations to ongoing support, our team is dedicated to helping you achieve your health goals

(Lausanne) 11 , 622589 (2020)

Our team of professionals conducts thorough consultations to assess your suitability for semaglutide GLP-1, ensuring the treatment is safe and effective for you

Its essential to discuss risk and benefits with your healthcare provider and to be aware of the potential side effect in order to manage them effectively: Nausea and vomiting : These are the most common side effects and usually decrease over time